iCuraDx provides a comprehensive and highly scalable suite of genomics services designed to accelerate drug development, biomarker discovery, and precision medicine research. Their fully equipped molecular laboratory offers Next-Generation Sequencing (NGS), digital PCR (dPCR), quantitative PCR (qPCR), and real-time PCR, delivering sensitive, accurate, and reproducible results for both preclinical and clinical studies. These platforms enable researchers to detect low-frequency variants, quantify gene expression, measure viral vectors, and profile tumor biology with exceptional clarity.

With deep expertise in oncology genomics, iCuraDx supports tumor profiling, targeted cancer panels, gene therapy analysis, and immune-related biomarker characterization. Their capabilities extend into advanced spatial transcriptomics and whole transcriptome sequencing, allowing sponsors to integrate spatial and molecular data for a more complete understanding of the tumor microenvironment and disease biology. This makes iCuraDx an ideal partner for researchers seeking high-resolution genomic insights that drive translational breakthroughs.

To support complex pipelines and large-scale data needs, iCuraDx develops custom bioinformatics workflows, including AI-enabled biomarker discovery, automated variant calling, expression analytics, and customized reporting. Every project is supported by experienced molecular scientists who ensure data quality, interpretability, and regulatory alignment.

Whether you’re advancing an oncology program, characterizing gene therapy vectors, validating biomarkers, or building AI-driven diagnostic models, iCuraDx delivers reliable, clinically aligned genomics services that help move your research forward with speed and confidence. Reliable data, expert support, and cutting-edge technology—everything you need to power next-generation biomedical innovation.